Miles Fisher graduated from the University of Glasgow in 1979. He received his MD in 1988 for his thesis on ‘Evidence for a diabetic cardiopathy.’ He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010 he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-14, was the President of the Scottish Society of Physicians for 2015-16, and Co-chair of Scottish Heart & Arterial disease Risk Prevention (SHARP) in 2017.
He was on the steering committee of the DIGAMI 2 study and was the Scottish co-ordinator. He was an events adjudicator for the HOPE, HOPE-TOO, and cardiovascular outcome trials, and for the albiglutide Harmony phase 3 development programme. He has been involved in guideline development for the Scottish Intercollegiate Guidelines Network (SIGN) and the European Society of Cardiology (ESC) and in guideline reviewing for SIGN, ESC, European Association for the Study of Diabetes (EASD) & NICE.
He has interests in diabetes and the heart, hypoglycaemia, and new treatments for diabetes. He is the editor or co-editor of four books on heart disease in diabetes, three books on hypoglycaemia, and a book on SGLT2 inhibitors. He is the author or co-author of 49 book chapters, 81 original papers, 70 review articles, 33 leaders and editorials, 52 drug notes for Practical Diabetes and 15 drug notes for the British Journal of Cardiology. He was the co-author of the diabetes chapter in the 19th, 20th and 21st Editions of Davidson’s Principles and Practice of Medicine.